Evaluation of the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-Labeled SRT2104 in Healthy Male Subjects.

Trial Profile

Evaluation of the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-Labeled SRT2104 in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2011

At a glance

  • Drugs SRT 2104; SRT 2104
  • Indications Chronic obstructive pulmonary disease; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 15 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top